Supporting Clinical Research

Provocholine®

Aridol®



Partnerships



Training



Clinical Research Consultation



CRCE Courses



Blogs / Podcast



Guidelines / Publications



Speaking Engagements

Research is the key to better respiratory care

Airway challenge tests are objective measures that offer insight into investigational drugs. For over 30 years, these tests have been part of clinical trials as a means to identify the appropriate patient populations, assess response to therapies, and evaluate bioequivalence. Objective measures are more relevant than ever with the emergence and growth of specialized pharmacologic treatments such as biologics for respiratory conditions.



Download Detail Aid

We are the globally trusted partner in methacholine challenge testing.

Methapharm offers products and consultative services to support your clinical respiratory research that incorporates bronchial challenge testing.

Products

Services



Onsite and virtual training on bronchial challenge testing by clinical specialists



Support in the development and review of study protocols



Support in determining product volumes required



Full-service logistics and regulatory documentation

Legend

Asthma

FeNO

Provocholine

Aridol

Objective Testing (All Three Products)

Publications

The use of the mannitol test as an outcome measure in asthma intervention studies: a review and practical recommendations. Sverrild, 2021

Airway hyperresponsiveness to inhaled mannitol identifies a cluster of non-eosinophilic asthma patients with high symptom burden, Sverrild, 2021

The effect of tezepelumab on airway hyperresponsiveness to mannitol in asthma (UPSTREAM). Sverrild, 2021

Effect of tezepelumab on airway inflammatory cells, remodelling, and hyperresponsiveness in patients with moderate-to-severe uncontrolled asthma (CASCADE): a double-blind, randomised, placebo-controlled, phase 2 trial. Diver, 2021

Baseline FeNO Independently Predicts the Dupilumab Response in Patients With Moderate-to-Severe Asthma. Pavord, 2023

Early effectiveness of type-2 severe asthma treatment with dupilumab in a real-life setting; a FeNO-driven choice that leads to winning management. Carpagnano, 2022

Effects of an Anti-TSLP Antibody on Allergen-Induced Asthmatic Responses. Gauvreau, 2014

FDA Draft Guidance on Albuterol Sulfate, Mar 2020

Clinical equivalence testing of inhaled bronchodilators. Nair, 2009

We invite you to contact us at 1-800-287-7686 or via Email.